615 related articles for article (PubMed ID: 12422555)
1. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
4. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
[TBL] [Abstract][Full Text] [Related]
5. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
[TBL] [Abstract][Full Text] [Related]
7. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
8. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
Gabrielsson J; Green AR
J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
Mager DE
Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
[TBL] [Abstract][Full Text] [Related]
11. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
Agoram BM; Martin SW; van der Graaf PH
Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
[TBL] [Abstract][Full Text] [Related]
12. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
Toutain PL; Lees P
J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
[TBL] [Abstract][Full Text] [Related]
13. [How to measure the kinetics of biological effect of a drug].
Lechat P; Canet E
Therapie; 1997; 52(4):291-8. PubMed ID: 9437880
[TBL] [Abstract][Full Text] [Related]
14. Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials.
Hickey E
Curr Opin Drug Discov Devel; 2007 Jan; 10(1):49-52. PubMed ID: 17265741
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?
Barker CI; Standing JF; Turner MA; McElnay JC; Sharland M
Curr Opin Infect Dis; 2012 Jun; 25(3):235-42. PubMed ID: 22517604
[TBL] [Abstract][Full Text] [Related]
16. [Responsibilities of clinical pharmacology in the early phase of drug development].
Kuhlmann J
Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
[TBL] [Abstract][Full Text] [Related]
17. Population approaches in paediatrics.
Chatelut E
Fundam Clin Pharmacol; 2008 Dec; 22(6):575-8. PubMed ID: 19049657
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacology in development of new anticancer agents].
Sasaki Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
[TBL] [Abstract][Full Text] [Related]
19. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
20. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
